A new paradigm for immunotherapy in glioblastoma

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-03-31 DOI:10.1038/s41591-025-03607-9

Yosef Ellenbogen, Gelareh Zadeh

引用次数: 0

Abstract

A detailed case report shows that neoadjuvant combination immunotherapy can activate antitumor immunity and drive clinical benefit in newly diagnosed glioblastoma, revealing avenues for further research that could shift the treatment landscape to improve survival.

Abstract Image

查看原文本刊更多论文

胶质母细胞瘤免疫治疗的新模式

一份详细的病例报告显示，新辅助联合免疫治疗可以激活新诊断的胶质母细胞瘤的抗肿瘤免疫并推动临床获益，揭示了进一步研究的途径，可以改变治疗前景以提高生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.